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Abstract
Improving our understanding of the role of chromatin regulators in the initiation, development, 
and suppression of cancer and other devastating diseases is critical, as they are integral players in 
regulating DNA integrity and gene expression. Developing small molecule inhibitors for this 
target class with cellular activity is a crucial step toward elucidating their specific functions. We 
specifically targeted the DNA damage response protein, 53BP1, which uses its tandem tudor 
domain to recognize histone H4 dimethylated on lysine 20 (H4K20me2), a modification induced 
by double-strand DNA breaks. Through a cross-screening approach we identified UNC2170 (1) as 
a micromolar ligand of 53BP1, which demonstrates at least 17-fold selectivity for 53BP1 as 
compared to other methyl-lysine (Kme) binding proteins tested. Structural studies revealed that the 
tert-butyl amine of UNC2170 anchors the compound in the methyl-lysine (Kme) binding pocket 
of 53BP1, making it competitive with endogenous Kme substrates. X-ray crystallography also 
demonstrated that UNC2170 binds at the interface of two tudor domains of a 53BP1 dimer. 
Importantly, this compound functions as a 53BP1 antagonist in cellular lysates and shows cellular 
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activity by suppressing class switch recombination, a process which requires a functional 53BP1 
tudor domain. These results demonstrate that UNC2170 is a functionally active, fragment-like 
ligand for 53BP1.
One of the major processes regulating gene expression is the dynamic control of chromatin 
architecture. A key mechanism involved is the addition, recognition, and removal of post-
translational modifications (PTMs) on histone proteins by various enzymes and binding 
proteins.(1) In particular, the recognition of methylated lysine residues on histone tails by 
methyl-lysine (Kme) binding proteins is a critical event in chromatin regulation.(2, 3) These 
binding events recruit effector proteins and their macromolecular complexes to support 
defined gene activation and repression outcomes. Importantly, histone Kme binding has 
been shown to be misregulated in diseases including cancer and is essential to critical 
cellular processes such as DNA damage repair.(4–6)
53BP1 is a Kme binding protein that plays a central role in DNA Damage Repair (DDR) 
pathways and is recruited to sites of double-strand breaks (DSB). This process is dependent 
on the activity of ataxia telangiectasia mutated (ATM) kinase that regulates the DNA 
damage signaling response. Recruitment of 53BP1 can lead to cell cycle arrest and DNA 
damage repair, or lack thereof if there are defects or deficiencies present in the enzymes or 
proteins involved in this signaling cascade.(7–19) Cells deficient in 53BP1 prove to be 
viable but display a phenotype resembling mild ATM kinase-signaling defects due to the 
cell’s inability to properly respond to and repair DNA damage.(20, 21) 53BP1 knockout 
mice are viable, but are growth retarded, immune deficient, radiation sensitive, and cancer 
prone.(20) In addition, these mice display a defect in antibody class switch recombination 
(CSR) which also requires 53BP1 activity.(22) By testing different fragments of the 53BP1 
gene, it has been shown that the region that harbors its Kme binding tandem tudor domain 
(amino acids 1235–1709) is recruited to ionizing radiation (IR)-induced foci as efficiently as 
full-length, endogenous 53BP1.(23) Histone H4 lysine 20 dimethyl (H4K20me2) was 
identified as the primary PTM in histones recognized by the 53BP1 tandem tudor domain 
(TTD),(24) and this finding was subsequently supported by structural studies.(25) 
Additionally, the TTD of 53BP1 has been shown to bind to p53K382me2 and thereby 
increase the concentration of p53 at DNA damage sites.(26) Unlike H2AX phosphorylation, 
global levels of H4K20me2 do not increase after DNA damage; instead, 53BP1 recognizes 
histone H2A ubiquitylated at lysine 15 by RNF168 in response to DNA double-strand 
breaks.(27) 53BP1 recruitment is also facilitated by RNF168 ubiquitylation-dependent 
removal of L3MBTL1 and JMJD2A from H4K20me2 after DNA damage.(28, 29)
BRCA1 is a checkpoint and DNA damage repair gene that is required for maintenance of 
genomic integrity, and the inheritance of mutated BRCA1 is a major risk factor for breast 
and ovarian cancer.(30) BRCA1 knockout in mice is embryonic lethal,(31) and conditional 
knockout in the mammary gland results in low frequency and long latency of mammary 
tumor formation.(32) It was recently reported that the BRCA1 knockout developmental 
phenotype is rescued when placed on a 53BP1-null background, and adult mice that are null 
for both the 53BP1 and BRCA1 genes age normally and display a very low incidence of 
tumor formation.(33) The genomic instability in the BRCA1 knockout can be overcome 
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because the homologous recombination (HR) pathway is largely restored in cells lacking 
both BRCA1 and 53BP1.(34)
We hypothesized that a small molecule ligand that prevents Kme recognition by 53BP1 
would antagonize its biological activity in cells possessing BRCA1 mutations and lead to 
rescue of their genomic stability by restoration of the HR pathway. Notwithstanding the 
clinical challenges of cancer prevention strategies, the discovery of a small molecule in vivo 
probe for 53BP1 would enable this hypothesis to be tested preclinically, and the devastating 
effects of BRCA1 mutations, including prophylactic surgical interventions,(21) could 
perhaps be diminished. We therefore aimed to synthesize cell penetrant small molecules that 
would bind selectively to the tandem tudor domain of 53BP1 using structure-based design 
and iterative medicinal chemistry. Herein we report the initial results of this effort.
RESULTS AND DISCUSSION
A structure-based design approach was initiated by analyzing available crystal structure data 
of 53BP1 bound to an H4K20me2 peptide (PDB 2IG0).(25) The key interactions noted in 
this structure were a hydrogen-bond between the Kme basic amine and an aspartic acid 
(Asp1521), cation-π interactions between Kme2 and phenylalanine, tyrosine, and tryptophan 
residues within the aromatic binding cage (Tyr1502, Tyr1523, Phe1519, Trp1495), and a 
cation-π interaction between arginine 19 on the H4 peptide tail and a tryptophan residue 
(Trp1500).(25) Mutagenesis of the histone peptide had previously demonstrated that H18 
also contributes to binding, but this interaction was not clearly defined in the X-ray crystal 
structure.(25) To develop a more complete understanding of the binding interactions of the 
H4 peptide (amino acids 14–27) bound to 53BP1, isotope enriched (13C and 15N) NMR 
spectroscopy(35) was applied to determine the structure of the central residues of the 
H4K20me2 peptide bound to 53BP1 (PDB 2LVM).(36) It was observed that this central 
region of the H4 peptide corresponding to residues 15 to 22 adopts a “U-turn” conformation. 
Notably, in addition to the binding interactions with H4K20me2 and H4R19 that were 
detected in the crystal structure, further analysis revealed a pocket containing both acidic 
and hydrophobic residues that accommodates H4R17 and H4V21. It has also been shown 
that acetylation of H4K16 diminishes 53BP1 binding by disrupting a salt bridge between 
H4K16 and Glu1551.(36) Therefore, a small molecule that could occupy the methyl-lysine 
binding cage of 53BP1 and interact favorably with some of the surrounding residues would 
be expected to block 53BP1 binding to H4K20me2.
Our current efforts utilize a comprehensive cross-screening approach in order to evaluate all 
synthesized ligands against a panel of Kme reader domains. The Kme reader panel consists 
of 10 reader proteins from four different families: tudor domains (53BP1, UHRF1, PHF1, 
PHF19), chromodomains (CBX7), MBT domains (L3MBTL1, L3MBTL3, MBTD1), and 
PHD fingers (JARID1A, PHF23, UHRF1). These proteins were chosen largely based on 
available structural information, reader family representation, and biological relevance. 
Previously our lab reported an AlphaScreen bead-based proximity assay for Kme 
readers(37) and this screening tool was employed to initially assess 53BP1 binding. 
UNC2170 (1, Table 1) emerged as a preliminary 53BP1 hit from these cross-screening 
efforts. Because of the modest affinity of 1 (29 ± 7.4 µM) and its fragment-like nature (MW 
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= 313.24, ligand efficiency = 0.35, lipophilic ligand efficiency = 1.5)(38, 39), we profiled it 
at concentrations up to 500 µM versus our reader panel to better ascertain its selectivity, as 
this is of paramount importance for chemical probe development (Supplementary Figure 
S1).(40) This revealed promising levels of selectivity within this small but diverse sampling 
of Kme reader proteins, as 1 showed no affinity within the concentrations tested against any 
other members of the panel, including other tudor domain containing proteins and other 
readers of methylated H4K20 (Table 1). Additionally, isothermal titration calorimetry (ITC) 
experiments confirmed ligand binding, revealing a Kd of 22 ± 2.5 µM for UNC2170 against 
the 53BP1 tandem tudor domain (Figure 1).
Based on this initial data, we initiated synthetic efforts to prepare analogues of UNC2170 in 
order to evaluate structure-activity relationships (SAR) within this series and improve the 
affinity for 53BP1. For these SAR studies, all synthesized ligands were tested at 
concentrations up to 100 µM against our Kme panel to evaluate both their selectivity and 
potency. Analysis of UNC2170 suggested three primary areas for synthetic modification: the 
basic amine, the linker region, and the aromatic ring. SAR for each of these regions are 
discussed below.
It was hypothesized that the basic amine of UNC2170 would bind within the Kme binding 
pocket of 53BP1, similar to dimethyl-lysine. Exploration of the steric tolerance of the basic 
amine in 1 began by replacement of the secondary N-tert-butyl amine group with dimethyl 
amine (2) to more closely mimic the endogenous H4K20me2 substrate (Table 1). 
Interestingly, this compound showed no binding activity by AlphaScreen and this finding 
was confirmed by ITC (Supplementary Figure S2).
This result led us to hypothesize that the 53BP1 Kme binding pocket may have a preference 
for secondary amines over tertiary amines in the context of the UNC2170 framework, in 
contrast to its preference for dimethylated versus monomethylated lysine peptides.(25) 
Preparation of the isopropyl amino compound, 3, showed no activity against 53BP1 but 
interestingly, it was weakly active against some of the other tudor domain containing 
proteins in the panel (Table 1). Incorporation of other tertiary amines as in compound 4, 
where the secondary amine of UNC2170 is methylated, also showed no appreciable binding 
activity up to 500 µM as measured by AlphaScreen (Table 1 and Supplementary Figure 1a). 
ITC studies further confirmed that 4 has no measurable affinity for 53BP1, and therefore 
compound 4 (UNC2892) was selected as a negative control compound due to its inactivity 
and structural similarity to UNC2170 (1).
Further exploration of the ligand tolerance within the Kme binding pocket by replacement of 
the basic amine with an oxygen (5) resulted in no activity, as anticipated. We also 
investigated whether 53BP1 has similar Kme mimetic preferences as the MBT containing 
protein, L3MBTL1, as both bind the H4K20me2 mark. Compounds incorporating 
pyrrolidine have been shown to serve as effective ligands for such MBT domain containing 
proteins.(41–45) To test this we introduced a pyrrolidine amine to give compound 6 and 
found that this modification did not improve affinity towards 53BP1, confirming that Kme 
readers of the same histone mark do not necessarily have similar small molecule ligand 
preferences. Overall, our SAR exploration of the basic amine of UNC2170 (1) shows that a 
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sterically bulky, lipophilic secondary amine is preferred for binding in the Kme pocket of 
53BP1.
Prior to expanding our SAR studies to other portions of the molecule, we first sought to 
confirm that the N-tert-butyl amine of UNC2170 (1) was mimicking the endogenous Kme2 
ligand and binding within the Kme binding pocket. We prepared an active site mutant of 
53BP1 (D1521A) that no longer binds H4K20me2 due to loss of a salt bridge and hydrogen 
bond with Asp1521.(25) ITC demonstrated that binding of UNC2170 (1) was abrogated by 
the 53BP1 D1521A mutant (Supplementary Figure S2) which is consistent with the basic 
amine of UNC2170 (1) occupying the Kme reader pocket.
Various linkers to modify the distance and flexibility between the basic amine of UNC2170 
and the aromatic functional group were explored next (Table 2). Initial SAR efforts began 
with the substitution of a sulfonamide linker for the amide bond to give compound 7, 
resulting in loss of 53BP1 binding affinity. Conversion of the amide to a benzylamine as in 
compound 8 similarly abrogated binding. When the linker region between the amide bond 
and basic nitrogen was rigidified using two different cyclic variants (compounds 9 and 10), 
53BP1 activity was again lost. Additionally, lengthening the aliphatic chain between the 
amide bond and the amine as in compounds 11 and 12 resulted in inactivity, while 
shortening the linker (13) had a similar effect. Within this series, the propyl alkyl chain in 
compound 1 was found to be optimal.
We extended our SAR studies to the aromatic ring of UNC2170 by first assessing the 
contribution of the bromine to binding via preparation of compound 14, which showed no 
measurable binding to 53BP1 (Table 3). Furthermore, the bromine regioisomers, compounds 
15 and 16, were similarly inactive, suggesting that the bromine of UNC2170 is making a 
specific interaction with 53BP1. A halogen scan demonstrated that chlorine (17) and 
fluorine (18) provided no improvement in affinity, but replacement of the bromine with 
iodine was well tolerated (19, IC50 = 13 ± 4.8 µM). Consistent with this, we found that 
binding affinity is maintained when an isopropyl group (20) or a trifluoromethyl substituent 
(21) occupies the 3-position, suggesting that larger, more lipophilic substituents are 
preferred. The binding of 21 to 53BP1 was further confirmed by ITC (Supplementary Figure 
S2), which resulted in a Kd that correlated well with the AlphaScreen results (Kd = 10 ± 1.0 
µM). While the 3-trifluoromethyl analog was roughly equipotent to UNC2170 (1), activity 
was also specific to this regioisomer, as compound 22 with CF3 para to the amide is 
inactive. Replacement of the Br of 1 with a nitro group at the 3-position (23) also results in a 
loss in potency.
We hypothesized the halogenated 4-substituted pyridine derivatives, compounds 24 and 25, 
would increase the positive charge of the σ-hole of the bromine in UNC2170 and the CF3 in 
compound 21, in turn both increasing the likelihood of a halogen-hydrogen bond with the 
protein and improving binding.(46) These pyridine analogs resulted in a decrease in potency 
relative to their phenyl counterparts, suggesting that a potential halogen bond with 53BP1 is 
unlikely and instead favorable hydrophobic interactions are contributing to binding.
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A number of other modifications to the aromatic ring were tested, including the addition of 
amino and hydroxyl groups at the 2-, 4-, and 5-positions while maintaining a 3-bromo 
substituent. UNC2170 derivatives incorporating functionalized lactones, furans, 
benzofurans, and pyridines, as well as variable methylene linkers between the amide bond 
and aromatic ring were also prepared. All of these analogs resulted in compounds that were 
inactive against 53BP1. Overall, these findings demonstrate that limited manipulations can 
be performed to the aromatic core of UNC2170 while maintaining potency, and that 53BP1 
generally prefers analogs of UNC2170 that possess a lipophilic substituent at the 3-position.
To better understand the structural basis for UNC2170 binding, we co-crystallized the 
53BP1 tandem tudor domain with UNC2170 and solved its structure by X-ray 
crystallography at 1.5 Å resolution (PDB 4RG2). Interestingly, we found that under these 
conditions UNC2170 is bound to a 53BP1 dimer, making distinct interactions with both 
tudor domains (Figure 2a). This correlates well with the molar ratio observed by ITC (Figure 
1), which consistently produced an N value less than 1, suggesting a 2:1 ratio of protein to 
ligand. The structure revealed that the N-tert-butyl amine of UNC2170 is buried in the Kme 
binding pocket of one tudor domain (Figure 2b; magenta), driven largely by van der Waals 
interactions, hydrogen bonds, and electrostatic interactions. Due to the fact that the aromatic 
residues of both Kme pockets are greater than 5 Å from the amine, we anticipate that cation-
π interactions are a minor contribution to binding relative to the hydrogen bonds formed 
between the ligand and protein.
The basic amine of UNC2170 is about equidistant from Asp1521 in each protein binding 
pocket (2.8 Å and 2.6 Å), and is well positioned to interact with and make a critical 
hydrogen bond to Asp1521 in both proteins. The importance of this interaction is consistent 
with ITC data that shows that the Kme pocket mutant, D1521A, does not bind to UNC2170. 
Additionally, the amide nitrogen is also within hydrogen bonding distance of the Asp1521 
residue of one tudor domain, which is likely to further facilitate binding. The distance 
between the amine and the amide of UNC2170 therefore appears to be quite important in 
enabling a number of key interactions, and this sheds light on why changing the length of 
the aliphatic linker (compounds 11 – 13) impairs binding. The aliphatic linker and aromatic 
ring of UNC2170 is also nicely sandwiched between the dimer interface, packing against the 
surface of each protein unit.
Various series of analogs were prepared around UNC2170 beyond those presented above, 
many of which contained less subtle modifications; however, they all revealed a minimal 
tolerance to modification of the original ligand structure. The co-crystal structure assists in 
explaining this lack of SAR, as the interaction of UNC2170 with the 53BP1 dimer reveals 
that the ligand is encircled by both proteins and that there is limited space for modification. 
This is in contrast to our preliminary structural predictions based on UN2170 bound to a 
single 53BP1 tudor domain. We plan to utilize this novel binding mode in future efforts 
aimed at designing both UNC2170 related and structurally distinct inhibitors of 53PB1.
In addition to the X-ray structure, a 1H-15N HSQC NMR correlation spectrum of the tudor 
domain of 53BP1 was also obtained in the absence and presence of a 10-fold excess of 
UNC2170. Extensive changes in chemical shifts were observed (Figure 2c), further 
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confirming specific binding of the ligand to 53BP1. Exchange between the bound and 
unbound state was observed to be slow on the NMR chemical shift time scale which is 
surprising given the measured affinity of UNC2170.
To further evaluate whether UNC2170 is able to compete with Kme2 peptide substrates for 
binding, H4K20me2 and p53K382me2 peptide pull down assays were conducted. UNC2170 
was able to successfully displace the tandem tudor domain of a His-53BP1 fusion protein 
from both H4K20me2 and p53K382me2 peptides (Figure 3a). Additionally, UNC2170 
displaces His-53BP1 from immobilized p53K382me2 in a dose dependent fashion (Figure 
3b), resulting in an apparent IC50 of about 30 µM which is consistent with the results from 
other in vitro assays described above.
Additional chromatin release assays were conducted in HEK293 cell lysates to determine if 
UNC2170 could influence the amount of endogenous 53BP1 bound to chromatin. 
Purification of chromatin from HEK293 cells was followed by compound treatment for two 
hours at room temperature and subsequent separation of the solubilized proteins from those 
remaining on chromatin. Western blot analysis revealed that treatment with UNC2170 (500 
µM) resulted in a significant increase in soluble 53BP1 as compared to untreated lysates or 
lysates treated with UNC2892, the negative control compound (Figure 4a). This effect was 
found to be concentration dependent, as an increase in soluble 53BP1 was observed with 
increasing concentrations of UNC2170 (Figure 4b), and partial release of 53BP1 was 
detected at concentrations as low as 10 µM. This result is consistent with UNC2170 
antagonizing the interaction between the tudor domain of full-length 53BP1 and chromatin.
We next sought to evaluate the potential of UNC2170 to engage 53BP1 in a cellular context. 
The low molecular weight (313.24 g/mol) and clogP (~3.27) of UNC2170 suggested a priori 
that UNC2170 would be cell permeant. To confirm this and assess the suitability of the 
compound for cell studies, the cell permeability of UNC2170 was determined. We found 
that UNC2170 was indeed highly cell permeant with no significant measureable cellular 
efflux (efflux ratio = 1.2) as determined by a bi-directional Caco-2 cell permeability assay.
(47) Furthermore, UNC2170 has no measurable toxicity within the desired concentrations 
for cellular experiments, with cell toxicity only beginning to take effect at >10 mM as 
measured by a CellTiter-Glo luminescent cell-viability assay (Supplementary Figure S4).
Although the tandem tudor domains of 53BP1 are required for foci formation after ionizing 
radiation,(23) pretreatment of U2OS cells with UNC2170 (1 hour, 100 – 300 µM) did not 
significantly decrease the extent of endogenous 53BP1 foci formed following 5 Gy 
irradiation, and similar results were observed with UNC2982 (Supplementary Figure S5). To 
further support this, γH2AX foci were also quantified after compound treatment and no 
changes were observed. In addition, UNC2170 did not affect the apparent residence time of 
a GFP fusion protein containing the 53BP1 tudor domains as measured by fluorescence 
recovery after photobleaching (FRAP) experiments before or after ionizing radiation (10 
Gy). Recent evidence suggesting that 53BP1 is a bivalent histone modification reader due to 
its recognition of H2AK15ub by its ubiquitination-dependent recruitment (UDR) modif(27) 
is one possible explanation for the maintenance of 53BP1 recruitment to DSB sites upon 
treatment with UNC2170 in these assays. Overall, UNC2170 treatment does not appear to be 
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sufficient to block 53BP1 recruitment after ionizing radiation and a more potent ligand may 
be required for such activity.
As efficient B cell antibody class switch recombination (CSR) requires 53BP1 to have an 
active tudor domain and 53BP1 knockout mice are severely impaired in their ability to 
undergo CSR,(48, 49) we sought to determine whether UNC2170 would induce this same 
defect. Naive IgM+ B cells were stimulated to undergo isotype switching to IgG1 with LPS 
and Il-4, treated with UNC2170, UNC2892, or mock treated, and then the relative switching 
to IgG1 was determined by FACS analysis 3.5 days after compound treatment. B cells 
treated with UNC2170 (75 µM) underwent CSR 64% as effectively as untreated cells 
(Figure 5, Supplementary Figure S6), while treatment with UNC2892 had a much less 
significant inhibitory effect on CSR (89%). Although slightly higher and lower doses were 
tested (100 µM and 30 µM, respectively), treatment at 75 µM appears to be optimal in that 
the effects observed are specific to the active compound. Our attempts to probe the effect on 
CSR upon treatment with 300 µM of UNC2170 were unsuccessful, as this resulted in a 
reduction in cell viability. However, this effect could be mechanism related as UNC2892 
does not have the same anti-proliferative effects, and B cells undergoing CSR endure a high 
rate of DNA damage while proliferating rapidly and therefore represent a particularly 
sensitive cell subset. It has been reported previously that B cells stimulated from mice 
bearing a single 53BP1 D1518R amino acid substitution (this mutant is equivalent to 
D1521R in humans) switch at about 10% of wild type levels.(48) While the effect of 
UNC2170 is not as pronounced, treatment with UNC2170 clearly phenocopies the reduction 
in CSR seen in 53BP1 mutant B cells.
CONCLUSIONS
We have shown that the 53BP1 ligand, UNC2170, while only modestly potent, demonstrates 
at least 17-fold selectivity for 53BP1 as compared to nine other Kme reader proteins. The 
binding of UNC2170 is also dependent upon a functional tudor domain as demonstrated by 
site directed mutagenesis and ITC studies. A co-crystal structure revealed that the small 
molecule ligand binds within the same Kme binding pocket as endogenous Kme peptides. 
However, distinct from Kme peptide ligands, UNC2170 engages the binding pockets of two 
53BP1 tudor domains. This simple, relatively non-toxic ligand also exhibits modest activity 
as a 53BP1 antagonist in cellular lysates and has functional consequences in CSR assays 
consistent with its weak in vitro activity. A closely related negative control compound, 
UNC2892, lacks both in vitro and cellular effects, suggesting that the results observed with 
UNC2170 are indeed due to the inhibition of 53BP1. Thus, UNC2170 is a novel small 
molecule ligand of 53BP1, a Kme reader protein that has gained much attention recently due 
to its integral role in DNA damage repair and its link to BRCA1. Our preliminary SAR 
studies revealed only modest improvements in potency, and further exploitation of the 
structural data should facilitate the development of a high-quality chemical probe for 53BP1. 
This work also aids in demonstrating the potential for Kme readers to be modulated via 
small molecule intervention, despite the limited research in this field to date.
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The AlphaScreen assay was generally performed as previously described.(37) In brief, 
compound plates (1 µL at 10 mM highest concentration; 3-fold, 10-point dilutions in 
DMSO) were diluted in 1× assay buffer (20 mM TRIS pH 8.0, 25 mM NaCl, 2 mM DTT 
and 0.05% Tween-20) to 1 mM using a Multimek robotic pipettor (Nanoscreen) and 1 µL 
was spotted into the wells of 384-well low-volume Proxiplates (PerkinElmer). To these 
plates 9 µL of protein-peptide mix in 1× assay buffer was added by Multidrop (Thermo) to 
bring the final compound concentration to 100 µM and incubated for 30 min at room 
temperature. Next, 2 µL of a 1:1 mixture of streptavidin-conjugate donor and nickel-chelate 
acceptor beads (45 µg/mL in 1× assay buffer) were added and the plates were allowed to 
incubate for an additional 30 min in the dark at room temperature. After incubation, the 
plates were read on an EnVision multi-label reader equipped with an HTS AlphaScreen laser 
(Perkin Elmer). The IC50 values reported are the average of at least 3 values ± the standard 
deviation. When IC50 values for a single compound were not all active (< 100 µM) or 
inactive (> 100 µM), the IC50 values were calculated using 4-paramter curve fitting 
(GraphPad Prism 5) from replicate runs using averaged response values for each compound 
concentration.
Chromatin Fractionation Experiments
Chromatin was isolated from HEK293 cells. Cells were lysed in EBC-1 buffer (Tris pH 7.5, 
100mM NaCl, 0.5% NP-40, 1mM EDTA), nuclear pellets were collected, washed in EBC-1 
and resuspended in EBC-2 (Tris pH7.5, 300mM NaCl, 5mM CaCl2) for 30 minutes. The 
insoluble chromatin was pelleted and resuspended in EBC-2 for use in the release assay. 
This chromatin was incubated with the indicated concentration of compounds for 2 hrs at 
RT. The supernatant was collected and analyzed as the soluble fraction while the remaining 
pellet was resuspended in loading buffer, sonicated, and analyzed as the chromatin bound 
fraction. Anti-53BP1 (Sigma B4436) and anti-histone 3 (loading control) were used in 
western blots.
Crystallization
Purified 53BP1 (42 mg/mL) in 20 mM HEPES, pH 7.5, 150 mM NaCl, 0.5 mM TCEP was 
pre-incubated with 10 mM UNC2170 (dissolved in water) and the best crystals were 
obtained by vapor diffusion technique at 20 °C in sitting drops by mixing 1 µL of protein 
solution with 1 µL of reservoir solution containing 19% PEG3350, 150 mM DL-malic acid 
pH 7.2. For cryoprotection, the crystals were soaked in the reservoir solution supplemented 
with 15% ethylene glycol (v/v) for 60 s before flash freezing in liquid N2.
CSR Experiments
B cell isolation and culture have been previously described.(50) In brief, primary naive B-
lymphocytes from WT C57/BL6 mouse spleens were purified by negative selection with 
anti-CD43 beads (Miltenyi Biotec) and cultured in RPMI 1640, 1 mM sodium pyruvate, 
10% fetal bovine serum (Atlanta Biologicals,), 50 uM 2-mercaptoethanol, 25 µg/ml 
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Lipopolysaccharide(LPS) and 5 ng/ml IL-4 (Sigma-Aldrich). Inhibitors were added at 12 
hours culture and cells were analyzed 72 hours later. Cultured splenocytes were stained with 
anti–mouse IgG1 antibodies (BD). Dead cells were excluded on the basis of forward-side 
scatter and propidium iodide staining. Cells were analyzed on a LSRFortessa (BD) and data 
was analyzed with FloJo software. Data is the summary of triplicate culture analysis of 
100uM (n=4), 75uM (n=3) and 30uM (n=3) independent experiments. Statistical 
significance was determined by a two-tailed Student's t test assuming unequal variance, p 
values indicated.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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H4K20me2 histone H4, lysine 20 dimethyl
H4K20me1-2 mono- or dimethylation of lysine 20 on histone 4
SAR structure activity relationships
PTM post-translational modification
53BP1 Tumor suppressor p53 binding protein 1
PHD Plant homeodomain
MBT malignant brain tumor
L3MBTL3 Lethal(3)malignant brain tumor-like protein 3
L3MBTL1 Lethal(3)malignant brain tumor-like protein 1
MBTD1 MBT domain containing 1
PHF1 PHD finger protein 1
PHF19 PHD finger protein 19
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PHD23 PHD finger 23
JARID1A Lysine (K)-specific demethylase 5A
CBX7 Chromobox homolog 7
UHRF1-TTD Ubiquitin-like, containing PHD and RING finger domains, 1- tandem 
tudor domain
UHRF1-TTD Ubiquitin-like, containing PHD and RING finger domains, 1- tandem 
tudor domain + PHD finger domain
ITC isothermal titration calorimetry
DDR DNA Damage Response
CSR Class Switch Recombination.
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ITC analysis of 53BP1 binding to UNC2170 (1), revealing a Kd of 22 ± 2.5 µM.
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Crystallography and NMR evidence for UNC2170 (1) binding to 53BP1. (a) Co-crystal 
structure of 1 (cyan) bound to the 53BP1 tudor domain dimer (PDB 4RG2). One 53BP1 
protein unit is shown in light gray and the other in dark gray, with the residues that interact 
with UNC2170 shown in fuchsia and green, respectively. (b) View of the protein surface of 
each 53BP1 tudor domain that interacts with UNC2170 (the two domains shown in (a) are 
separated and rotated); color coding is the same as in (a). (c) Overlay of the 1H-15N HSQC 
correlation spectra of 53BP1 in the free state (black) and in the presence of 10-fold molar 
excess UNC2170 (red).
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Western blot analysis following competitive in-solution peptide pulldown assays with 
His-53BP1 TTD and (a) 500 µM UNC2170 or (b) the indicated concentration of UNC2170 
shows inhibition of the interaction between the 53BP1 TTD and H4K20me2 and 
p53K382me2 peptides. UNC2170 displaces His-53BP1 from immobilized p53K382me2 in a 
dose dependent fashion.
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Western blot analysis of HEK293 cell lysates biochemically separated into chromatin and 
soluble fractions after treatment with (a) 500 µM UNC2170 or UNC2892 or (b) the 
indicated concentration of UNC2170 for 2 hours at room temperature. Anti-Histone 3 is 
shown as an input control.
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Summary of relative CSR to IgG1 switching in naive splenocytes cultured with LPS and 
IL-4 for 3.5 days in the presence of UNC2170 or UNC2892 at the indicated concentrations 
as compared to untreated cells. Averages represent triplicate cultures from four independent 
experiments. P value (* p<0.0001) was determined by a two-tailed t test assuming unequal 
variance.
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